Clinical and laboratory characteristics of patients with precursor B-ALL
| Characteristic . | Definitive risk classification, n (%)* . | P . | |
|---|---|---|---|
| Low risk (n = 101) . | Other (n = 274) . | ||
| Age, y | <.0001 | ||
| Median | 4.0 | 5.1 | |
| Range | 1.2-9.8 | 1.0-17.7 | |
| Sex | .7428 | ||
| Male | 53 (52.5) | 149 (54.4) | |
| Female | 48 (47.5) | 125 (45.6) | |
| Race | .1646 | ||
| Mixed | 66 (65.3) | 176 (64.2) | |
| White | 31 (30.7) | 95 (34.7) | |
| Black | 4 (4.0) | 3 (1.1) | |
| WBC count, ×109/L | .0011 | ||
| Median | 7.0 | 9.0 | |
| Range | 1.0-89.9 | 4.9-482.8 | |
| CNS | .0578 | ||
| Status 1 | 91 (90.1) | 240 (87.6) | |
| Status 2 | 0 | 2 (0.7) | |
| Status 3 | 0 | 13 (4.7) | |
| TP with blasts | 1 (1.0) | 7 (2.6) | |
| TP without blasts | 9 (8.9) | 12 (4.4) | |
| NCI risk | <.0001 | ||
| Standard | 97 (96.0) | 167 (60.9) | |
| High | 4 (4.0) | 107 (39.1) | |
| DNA index | .1459 | ||
| ≥1.16 | 29 (28.7) | 55 (20.1) | |
| Other | 69 (68.3) | 214 (78.1) | |
| No data | 3 (3.0) | 5 (1.8) | |
| Genotype | <.0001 | ||
| Negative | 66 (65.3) | 197 (71.9) | |
| ETV6-RUNX1 | 31 (30.7) | 29 (10.6) | |
| TCF3-PBX1 | 0 | 27 (9.9) | |
| BCR-ABL1 | 0 | 10 (3.6) | |
| KMT2A-AFF1 | 0 | 3 (1.1) | |
| KTM2A-MMLT1 | 0 (0) | 1 (0.4) | |
| No data | 4 (4.0) | 7 (2.6) | |
| MRD at d 19, % | <.0001 | ||
| <0.01 | 101 (100.0) | 49 (17.9) | |
| ≥0.01 | 0 | 211 (77.0) | |
| Inconclusive | 0 | 14 (5.1) | |
| Complete remission | .0652 | ||
| Yes | 101 (100.0) | 265 (96.7) | |
| No | 0 | 9 (3.3) | |
| Characteristic . | Definitive risk classification, n (%)* . | P . | |
|---|---|---|---|
| Low risk (n = 101) . | Other (n = 274) . | ||
| Age, y | <.0001 | ||
| Median | 4.0 | 5.1 | |
| Range | 1.2-9.8 | 1.0-17.7 | |
| Sex | .7428 | ||
| Male | 53 (52.5) | 149 (54.4) | |
| Female | 48 (47.5) | 125 (45.6) | |
| Race | .1646 | ||
| Mixed | 66 (65.3) | 176 (64.2) | |
| White | 31 (30.7) | 95 (34.7) | |
| Black | 4 (4.0) | 3 (1.1) | |
| WBC count, ×109/L | .0011 | ||
| Median | 7.0 | 9.0 | |
| Range | 1.0-89.9 | 4.9-482.8 | |
| CNS | .0578 | ||
| Status 1 | 91 (90.1) | 240 (87.6) | |
| Status 2 | 0 | 2 (0.7) | |
| Status 3 | 0 | 13 (4.7) | |
| TP with blasts | 1 (1.0) | 7 (2.6) | |
| TP without blasts | 9 (8.9) | 12 (4.4) | |
| NCI risk | <.0001 | ||
| Standard | 97 (96.0) | 167 (60.9) | |
| High | 4 (4.0) | 107 (39.1) | |
| DNA index | .1459 | ||
| ≥1.16 | 29 (28.7) | 55 (20.1) | |
| Other | 69 (68.3) | 214 (78.1) | |
| No data | 3 (3.0) | 5 (1.8) | |
| Genotype | <.0001 | ||
| Negative | 66 (65.3) | 197 (71.9) | |
| ETV6-RUNX1 | 31 (30.7) | 29 (10.6) | |
| TCF3-PBX1 | 0 | 27 (9.9) | |
| BCR-ABL1 | 0 | 10 (3.6) | |
| KMT2A-AFF1 | 0 | 3 (1.1) | |
| KTM2A-MMLT1 | 0 (0) | 1 (0.4) | |
| No data | 4 (4.0) | 7 (2.6) | |
| MRD at d 19, % | <.0001 | ||
| <0.01 | 101 (100.0) | 49 (17.9) | |
| ≥0.01 | 0 | 211 (77.0) | |
| Inconclusive | 0 | 14 (5.1) | |
| Complete remission | .0652 | ||
| Yes | 101 (100.0) | 265 (96.7) | |
| No | 0 | 9 (3.3) | |
NCI, National Cancer Institute.
Four patients were not evaluable for MRD on day 19.